Tech Company Financing Transactions
Inotek Pharmaceuticals Funding Round
Pitango Venture Capital, MedImmune Ventures and Rho Ventures participated in a $25 million Series B funding round for Inotek Pharmaceuticals. This venture round was recorded on 8/30/2005.
Transaction Overview
Company Name
Announced On
8/30/2005
Transaction Type
Venture Equity
Amount
$25,000,000
Round
Series B
Investors
Proceeds Purpose
These resources will enable us to fund the further development of our growing pipeline of products, including our four products in Phase 1 and Phase 2 clinical development as well as our three pre-clinical candidates.
Company Information
Company Status
Publicly-held
Industry
Biopharmaceutical
Mailing Address
1202 Water St.
Walnut Creek, CA 94597
USA
Walnut Creek, CA 94597
USA
Phone
Website
Email Address
Overview
Inotek Pharmaceuticals is a clinical-stage, publicly traded, biopharmaceutical company focused on the discovery, development and commercialization of novel therapies to treat glaucoma and other serious diseases of the eye.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
David Southwell
Chief Medical Officer
Rudolf Baumgartner
Chief Scientific Officer
William McVicar
VP - Finance
Dale Ritter
Browse more venture capital transactions:
Prev: 8/29/2005: Allylix venture capital transaction
Next: 8/30/2005: Renkoo venture capital transaction
Share this article
News on VC Transactions
We do our best to report on every notable VC transaction. VC investment data records reported here come from a variety of public sources. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs